The expected launch of drugs by the leading players such as Acceleron Pharma Inc., United Therapeutics, Altavant Sciences, Aerovate Therapeutics, Respira Therapeutics, and others in the pipeline shall fuel the pulmonary arterial hypertension market's growth during the forecast period, i.e., 2022–2032.
LAS VEGAS, Sept. 20, 2022 /PRNewswire/ -- DelveInsight's Pulmonary Arterial Hypertension Market Insights report includes a comprehensive understanding of current treatment practices, pulmonary arterial hypertension emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), Japan].
Key Takeaways from the Pulmonary Arterial Hypertension Market Report
- As per DelveInsight estimates, the pulmonary arterial hypertension market size in the 7MM was approximately USD 4,775.54 million in 2021.
- As per our analysis, the total pulmonary arterial hypertension prevalent population in the 7MM was approximately 69K in 2021.
- Leading pulmonary arterial hypertension companies such as Pfizer, Eli Lilly and Company, United Therapeutics Corporation, Gilead Sciences, GSK, ICOS Corporation, Actelion Pharmaceuticals, Nippon Shinyaku, Bayer Group, Actelion Pharmaceuticals, CoTherix, Kaken Pharmaceutical, Sanofi-Aventis, Toray, Acceleron Pharma Inc., Altavant Sciences, Aerovate Therapeutics, Respira Therapeutics, Gossamer Bio Inc., Merck Sharp & Dohme Corp., Insmed Incorporated, Pharmaosa Biopharma Inc., Bial (Portela C S.A.), Liquida Technologies, Inc., Cereno Scientific AB, and others are developing novel pulmonary arterial hypertension drugs that can be available in the pulmonary arterial hypertension market in the upcoming years.
- The promising pulmonary arterial hypertension therapies in the pipeline include Aurora-GT, Sotatercept, Ralinepag, Rodatristat Ethyl, AV-101, RT234, GB002, MK5475, Treprostinil Palmitil, L606, Zamicastat (BIA-5-1058), LIQ-861, CS1, and others.
- The increase in pulmonary arterial hypertension market size is driven by the market entry of novel therapies, backed by payer willingness to reimburse, providing affordable coverage to a large addressable population.
Discover which therapies are expected to grab major pulmonary arterial hypertension drug market share @Pulmonary Arterial Hypertension Market Report
Pulmonary Arterial Hypertension Overview
Pulmonary arterial hypertension (PAH) is a chronic lung vascular disease that primarily affects the small pulmonary arterioles. PAH is most commonly idiopathic and is characterized by increased vascular resistance and pulmonary vasculature narrowing.
Progressive exercise dyspnea is the hallmark symptom of all forms of pulmonary hypertension, and it is frequently accompanied by fatigue and exhaustion. As pulmonary arterial hypertension symptoms are vague, there is frequently a long period between the onset of symptoms and the diagnosis.
Pulmonary arterial hypertension causes include high blood pressure, connective tissue disease, coronary artery disease, high blood pressure, and liver disease (cirrhosis). Several blood tests, a chest X-ray, an electrocardiogram, an echocardiogram, a right heart catheterization, and other tests are used for pulmonary arterial hypertension diagnosis.
Pulmonary Arterial Hypertension Epidemiology Segmentation
DelveInsight estimates that there was approximately 69K pulmonary arterial hypertension prevalent population in the 7MM in 2021.
Among the EU5 countries, France had the highest prevalence of pulmonary arterial hypertension in 2021.
The pulmonary arterial hypertension market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalent cases of Pulmonary Arterial Hypertension
- Diagnosed cases of Pulmonary Arterial Hypertension
- Gender-specific cases of Pulmonary Arterial Hypertension
- Subtype-specific cases of Pulmonary Arterial Hypertension
Download the report to understand which factors are driving pulmonary arterial hypertension epidemiology trends @Pulmonary Arterial Hypertension Epidemiological Insights
Pulmonary Arterial Hypertension Treatment Market
The diversity in pulmonary arterial hypertension treatment approaches is due to the various etiologies, which include idiopathic pulmonary hypertension, drug-induced pulmonary hypertension, connective tissue disorder, and congenital heart disease. The current pulmonary arterial hypertension treatment landscape includes using vasodilators and endothelial receptor antagonists. General measures such as supportive therapy, pharmacological treatment, and surgical treatment are used (PAH). The pharmacological treatment for pulmonary arterial hypertension is classified as calcium channel blockers (CCBs), endothelin receptor antagonists (ERAs), and phosphodiesterase-5 (PDE-5) inhibitors.
Revatio is a phosphodiesterase-5 (PDE-5) inhibitor approved for the treatment of pulmonary arterial hypertension in adults to improve exercise capacity and delay clinical worsening. Revatio is available as tablets, oral suspension, and injections for intravenous administration.
Selexipag (Uptravi) is a first-in-class, orally active selective prostacyclin IP receptor agonist. The FDA approved selexipag for the long-term treatment of pulmonary arterial hypertension in adults. Iloprost (Ventavis) is a second-generation structural analog of prostacyclin PGI2 that dilates the systemic and pulmonary arterial vascular beds and aids in treating pulmonary arterial hypertension. Ambrisentan (Letairis) is a type A endothelin receptor antagonist taken orally and used to treat pulmonary arterial hypertension.
To know more about the treatment for pulmonary arterial hypertension, visit @Pulmonary Arterial Hypertension Drug Treatment
Pulmonary Arterial Hypertension Pipeline Therapies and Key Companies
- Aurora-GT: United Therapeutics
- Sotatercept: Acceleron Pharma Inc.
- Ralinepag: United Therapeutics
- Rodatristat Ethyl: Altavant Sciences
- AV-101: Aerovate Therapeutics
- RT234: Respira Therapeutics
- GB002: Gossamer Bio Inc.
- MK5475: Merck Sharp & Dohme Corp.
- Treprostinil Palmitil: Insmed Incorporated
- L606: Pharmaosa Biopharma Inc.
- Zamicastat (BIA-5-1058): Bial (Portela C S.A.)
- LIQ-861: Liquida Technologies, Inc.
- CS1: Cereno Scientific AB
Learn more about the pulmonary arterial hypertension therapies in clinical trials @Pulmonary Arterial Hypertension Treatment
Pulmonary Arterial Hypertension Market Dynamics
The pulmonary arterial hypertension market dynamics are rapidly changing, with the most significant advancement in recent years. The pulmonary arterial hypertension market is expected to evolve in the coming years as key players in the pulmonary arterial hypertension treatment regime are involved in developing novel therapies. Additionally, the increase in awareness and disease prevalence also contributed to the growth of the pulmonary arterial hypertension market.
Moreover, the recent advances in pharmacotherapy for pulmonary arterial hypertension have resulted in novel FDA approvals of agents such as ERAs, nitric oxide modulators, and prostacyclin therapies targeting the underlying pulmonary arterial hypertension pathophysiology; these therapeutic options in the pulmonary arterial hypertension market have increased dramatically over the last decades. The increased use of pharmacological interventions targeting the prostacyclin, endothelin, and NO pathways has significantly improved the pulmonary arterial hypertension market.
However, despite extensive research and clinical development, pulmonary arterial hypertension remains a fatal disease with no cure. Despite the preclinical model's success, fruitful transfer to human disease with positive results in clinical trials was limited by utilizing several potential novel approaches targeting cellular GPCRs, metabolism, growth factor receptors, ion channels, transcription factors, and inflammation. In addition, the unawareness about the disease, along with unreported and undiagnosed cases, remains the primary aspect that hinders the growth of the pulmonary arterial hypertension market.
Report Metrics |
Details |
Study Period |
2019–2032 |
Coverage |
7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] |
Base Year |
2021 |
Market CAGR |
0.56 % |
Market Size in 2021 |
4.77 Billion |
Key Pulmonary Arterial Hypertension Companies |
Pfizer, Eli Lilly and Company, United Therapeutics Corporation, Gilead Sciences, GSK, ICOS Corporation, Actelion Pharmaceuticals, Nippon Shinyaku, Bayer Group, Actelion Pharmaceuticals, Co Therix, Kaken Pharmaceutical, Sanofi-Aventis, Toray, Acceleron Pharma Inc., Altavant Sciences, Aerovate Therapeutics, Respira Therapeutics, Gossamer Bio Inc., Merck Sharp & Dohme Corp., Insmed Incorporated, Pharmaosa Biopharma Inc., Bial (Portela C S.A.), Liquida Technologies, Inc., Cereno Scientific AB, and others |
Key Pulmonary Arterial Hypertension Therapies |
Aurora-GT, Sotatercept, Ralinepag, Rodatristat Ethyl, AV-101, RT234, GB002, MK5475, Treprostinil Palmitil, L606, Zamicastat (BIA-5-1058), LIQ-861, CS1, and others |
Scope of the Pulmonary Arterial Hypertension Market Report
- Therapeutic Assessment: Pulmonary Arterial Hypertension current marketed and emerging therapies
- Pulmonary Arterial Hypertension Market Dynamics: Pulmonary Arterial Hypertension market drivers and barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
- Unmet Needs, KOL's views, Analyst's views, Pulmonary Arterial Hypertension Market Access and Reimbursement
Discover more about pulmonary arterial hypertension medications in development @Pulmonary Arterial Hypertension Clinical Trials
Table of Contents
1. |
Pulmonary Arterial Hypertension Market Key Insights |
2. |
Pulmonary Arterial Hypertension Market Report Introduction |
3. |
Pulmonary Arterial Hypertension Market Overview at a Glance |
4. |
Pulmonary Arterial Hypertension Market Executive Summary |
5. |
Disease Background and Overview |
6. |
Pulmonary Arterial Hypertension Treatment and Management |
7. |
Pulmonary Arterial Hypertension Epidemiology and Patient Population |
8. |
Patient Journey |
9. |
Pulmonary Arterial Hypertension Marketed Drugs |
10. |
Pulmonary Arterial Hypertension Emerging Drugs |
11. |
7MM Pulmonary Arterial Hypertension Market Analysis |
12. |
Pulmonary Arterial Hypertension Market Outlook |
13. |
Potential of Current and Emerging Therapies |
14. |
KOL Views |
15. |
Pulmonary Arterial Hypertension Market Drivers |
16. |
Pulmonary Arterial Hypertension Market Barriers |
17. |
Unmet Needs |
18. |
SWOT Analysis |
19. |
Appendix |
20. |
DelveInsight Capabilities |
21. |
Disclaimer |
22. |
About DelveInsight |
Related Reports
Pulmonary Arterial Hypertension Epidemiology
Pulmonary Arterial Hypertension Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical, and forecasted pulmonary arterial hypertension epidemiology in the 7MM.
Pulmonary Arterial Hypertension Pipeline
Pulmonary Arterial Hypertension Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key pulmonary arterial hypertension companies, including Actelion Pharmaceuticals, Co Therix, Kaken Pharmaceutical, Sanofi-Aventis, Toray, Acceleron Pharma Inc., among others.
Pulmonary Hypertension Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key pulmonary hypertension companies, including Cumberland Pharmaceuticals, AstraZeneca, Aerovate Therapeutics, Celon Pharma, Camurus, ATXA Therapeutics, among others.
Pulmonary Hypertension Pipeline
Pulmonary Hypertension Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key pulmonary arterial hypertension companies, including Reata Pharmaceuticals, Pharmosa BioPharm, United Therapeutics Corporation, Acceleron Pharma, Bellerophon Therapeutics, among others.
Pulmonary Hypertension Epidemiology Forecast
Pulmonary Hypertension Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted pulmonary hypertension epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Cardiac Output Monitors Market
Cardiac Output Monitors Market Insight, Competitive Landscape, and Market Forecast – 2027 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key cardiac output monitors companies, including Osypka Medical GmbH, CNSystems Medizintechnik GmbH., Uscom, Deltex Medical Limited, among others.
Other Trending Reports
Goitre Market | Thymus Cancer Market | US Healthcare Outlook Report | Venous Stenosis Market | Negative Pressure Wound Therapy Systems Market | Metrorrhagia Market | Dysfunctional Uterine Bleeding Market | Hypereosinophilic Syndrome Market | Age-related Vision Dysfunction Market | Dental Lasers Market | CRISPR Therapies Pipeline Insight | Cell And Gene Therapy For Multiple Myeloma Market | Drug Hypersensitivity Market | Dysthymia Market | Persistent Depressive Disorder Market | Cancer Vaccines Market | Weight Loss/Weight Management (Obesity) Market | Food Allergy Market | Obsessive-Compulsive Disorder Market | Tumor Ablation Market | Physiotherapy Equipment Market | CAR-T Pipeline Insight | Anti-hypertension Market | Radiofrequency Ablation Devices Market | Global Messenger RNA (mRNA)-based Vaccines and Therapeutics Market | Gastro Intestinal Bleeding Market | Trastuzumab Biosimilars Insight | Varicose Veins Market | Germ Cell Tumor Market | Intracardiac Echocardiography Devices Market | India Healthcare Outlook Report | Crows Feet Market Insight | Seborrhoeic Dermatitis Market | Injectable Drug Delivery Devices Market | Structural Heart Devices Market | Substance (Drug) Abuse Market
Related Healthcare Blogs
Pulmonary Arterial Hypertension Treatment Space
Upcoming Cardiovascular Diseases Drugs
Key Companies in the Cardiology Segment
Additionally, get in touch with our business executive to explore @Healthcare Due Diligence Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect with us on LinkedIn|Facebook|Twitter
Contact Us
Shruti Thakur
[email protected]
+1(919)321-6187
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
SOURCE DelveInsight Business Research LLP
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article